Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to all known beta-lactam antibiotics which is the most widely used groups in antibiotics. Absence of appropriate MRSA treatment in terms of drug and vaccination has threatened public health and has increased healthcare burden worldwide. Recently, S. aureus. wall teichoic acid (WTA), that is displayed on peptidoglycan cell wall, has been reported to function as recognition molecule in immunogenesis between S. aureus. and host. Also, MRSA have been found to have specific WTA that possibly prevents recognition of host’s biomolecules during immune response and helps MRSA viable in host. This implies that WTA can be a new target molecule for the development of new antibiotics or vaccines against MRSA. Wall teichoic acid (WTA) of S. aureus. is mainly composed of alditol phosphate repeating units, tailored with alanine and GlcNAc. Because of their microheterogeneity, pure well-defined WTAs for biological or immunological evaluation cannot be obtained from natural sources. We here present a systematically designed and synthesized building blocks for the synthesis of series of ribitol phosphate (RboP) oligomers. Streamlined solution phase phosphoramidite chemistry enabled us the rapid generation of well-defined ribitol-based WTA oligomers and evaluation of their biological activities.With the ease in the synthesis of phospho-ribitol building blocks and oligomers, plenty of different analogues in terms of length, substituents on C4 and stereochemistry would be synthesized with precisely defined structures. Those could pave the way to rationalize MRSA vaccine with high efficiency in near future.